Viridian Therapeutics, Inc.
VRDN
$30.43
-$1.02-3.24%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -17.46% | -50.87% | -41.35% | -13.55% | -18.66% |
| Total Depreciation and Amortization | -44.93% | -13.78% | -11.01% | -6.20% | 46.72% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -24.62% | -44.05% | -53.61% | -56.55% | 1.24% |
| Change in Net Operating Assets | -492.15% | -29.40% | 108.63% | 201.84% | 289.54% |
| Cash from Operations | -65.48% | -83.68% | -67.09% | -26.14% | -9.31% |
| Capital Expenditure | 17.08% | 3.78% | 23.75% | 43.10% | 58.83% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 171.44% | 114.21% | 106.74% | -144.38% | -221.92% |
| Cash from Investing | 171.23% | 113.91% | 106.45% | -142.60% | -219.04% |
| Total Debt Issued | -- | -- | -- | -- | -100.00% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -89.58% | -12.69% | -13.62% | 213.15% | 1,322.54% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -100.00% | -67.19% | -67.19% | -67.19% | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 95.39% | 26.87% | 26.09% | -118.77% | -1,884.78% |
| Cash from Financing | -90.93% | -25.81% | -26.53% | 102.83% | 1,077.70% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -134.57% | -53.09% | 686.12% | 93.87% | 138.14% |